Cholesterol gallstone disease (CGS) is one of the most prevalent gastrointestinal conditions, affecting up to 20% of adults worldwide [
1]. This bile disorder, caused by cholesterol supersaturation, can result in severe complications such as cholecystitis, cholangitis, and biliary pancreatitis. In the United States alone, more than 700,000 cholecystectomies are performed annually, underscoring the substantial burden CGS places on patients and healthcare systems [
1,
2]. At the molecular level, CGS pathogenesis centers around the ATP-binding cassette subfamily G members 5 and 8 (ABCG5/ABCG8), which play essential roles in cholesterol transport into bile and maintaining bile composition [
3]. Dysfunction of ABCG5/ABCG8 disrupts cholesterol efflux and leads to bile supersaturation, ultimately resulting in gallstone formation [
3].
Recent research highlights the strong association between CGS and metabolic dysfunction-associated steatotic liver disease (MASLD), particularly its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). MASH is marked by chronic liver inflammation and fibrosis, often linked to metabolic syndrome and type 2 diabetes mellitus [
4,
5]. These pathological changes impair bile acid synthesis and secretion, disrupting bile homeostasis and exacerbating CGS risk [
6,
7]. Furthermore, the interplay between cholesterol metabolism and inflammatory signaling in MASLD accelerates CGS progression, underlining the positive correlation of liver and biliary pathologies [
8]. However, the precise molecular mechanisms linking MASH and CGS still remain poorly defined [
9]. Recent studies have suggested that Golgi membrane protein 1 (GOLM1) may act as a key regulator in the pathological progression of MASH and CGS. Suppression of GOLM1 has been shown to cause intracellular accumulation of cholesteryl esters, highlighting its role in regulating cholesterol efflux [
10,
11]. Furthermore, GOLM1 expression is closely associated with major pathological features of MASH, such as hepatic inflammation and fibrosis [
12,
13]. Inflammatory cytokines, including interleukin-1β (IL-1β), have been recognized as important regulators of GOLM1 expression [
13,
14], further supporting the role of GOLM1 in the interaction between hepatic inflammatory responses and cholesterol metabolism. These findings suggest that GOLM1 plays an important role in coordinating the pathological mechanisms involved in both MASH and CGS.
In the latest issue of
Clinical and Molecular Hepatology, Li et al. [
15] present an in-depth investigation into the molecular mechanisms of GOLM1-OPN-ABCG5 axis during pathogenesis of MASH and CGS. The authors leveraged UK Biobank data to examine the molecular association between MASH and gallstone formation. The authors reported a significantly higher prevalence of gallstones in MASH patients compared to those with simple steatosis or healthy controls. These findings suggested a potential association between MASH and gallstone formation, distinct from simple steatosis, and underscored the need for mechanistic studies exploring cholesterol-bile metabolism in MASH-mediated gallstone formation. Using a high-fat diet (HFD)-induced MASH mouse model, the authors demonstrated fundamental roles of GOLM1 in gallstone formation. MASH mice exhibited increased GOLM1 expression, elevated levels of pro-inflammatory cytokines (IL-1β, IL-6), and a gallstone formation rate of 75%. Conversely, GOLM1-knockout (GOLM1−/−) mice showed a dramatic reduction in gallstone formation (16.7%), accompanied by lower bile cholesterol levels and decreased gene expression of ABCG5. These findings highlighted the significant role of GOLM1 in regulating ABCG5 gene expression, contributing to bile cholesterol homeostasis and mitigating gallstone formation.
Further experiments revealed that GOLM1 overexpression increased ABCG5 levels and bile cholesterol, underscoring its bidirectional role in the regulation of bile composition. The authors found that osteopontin (OPN) is a critical mediator in the GOLM1-ABCG5 axis. As consistent, GOLM1-knockout mice exhibited significant reduction of OPN gene expression while GOLM1 overexpression positively correlated with elevated OPN levels. Functional analyses demonstrated that OPN deficiency decreased ABCG5 expression and bile cholesterol, while OPN overexpression reversed these effects. Notably, OPN overexpression partially restored ABCG5 levels and bile cholesterol in GOLM1-deficient models, highlighting OPN as an important factor in the GOLM1-ABCG5 axis for bile cholesterol modulation. Under inflammatory conditions, GOLM1 translocates to the nucleus, where it binds directly to a specific region (-267 to -127) of the OPN promoter to activate transcription. Activated OPN stabilized ABCG5/ABCG8, maintaining bile composition and preventing gallstone formation. The authors further demonstrated that IL-1β-driven inflammation enhanced the GOLM1-OPN-ABCG5 axis, linking inflammatory pathways to dysregulated bile metabolism. These findings build on prior studies demonstrating GOLM1’s role in regulating inflammatory cytokines and contributing to bile metabolism disorders (
Fig. 1) [
13,
14,
16].
Analysis of liver tissue samples from MASH patients revealed significantly elevated IL-1β, GOLM1, OPN, and ABCG5 expression in patients with gallstones compared to those without, despite similar hepatic cholesterol levels. These findings suggest that inflammatory and metabolic factors are central to gallstone formation in the context of MASH. This study suggests the GOLM1-OPN-ABCG5 axis as a critical pathway linking pathogenic progression of MASH and CGS, providing a robust foundation for therapeutic development. Future studies should evaluate whether GOLM1 inhibition affects alternative bile acid synthesis pathways, such as CYP27A1 and CYP7B1 [
17]. These alternative bile acid synthesis pathways may undermine the efficacy of GOLM1-targeted therapies, necessitating comprehensive evaluations to ensure their stability and effectiveness. The impact of GOLM1 inhibition on bile acid metabolism and gut microbiota should be thoroughly investigated, as changes in the bile acid pool may alter systemic metabolism and immune responses [
18]. Exploring the potential for combination of GOLM1 inhibitors with FXR agonists or MASLD treatments, including PPAR-γ agonists and FGF21 analogs, offers promising therapeutic opportunities [
19]. FXR is a key regulator of bile acid metabolism and inflammation, thus GOLM1 inhibition could synergistically enhance therapeutic outcomes with FXR agonists [
18].
In conclusion, the GOLM1-OPN-ABCG5 axis plays a pivotal role in linking inflammation and metabolism, highlighting GOLM1 as a potential therapeutic target for treating CGS in MASH patients. Comprehensive research will pave the way for personalized GOLM1-based therapies, revolutionizing the treatment of metabolic liver diseases and related metabolic disorders.
FOOTNOTES
-
Authors’ contribution
N.H.: Writing – Review & Editing. S.F.: Writing – Original Draft Preparation, Review & Editing. Corresponding author.
-
Acknowledgements
This work was supported by Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (RS-2024-00437692).
-
Conflicts of Interest
The authors have no conflicts to disclose.
Figure 1.Schematic representation of the role of MASH-induced inflammation in gallstone formation through the GOLM1-OPN-ABCG5 axis. MASH, metabolic dysfunction-associated steatohepatitis; IL-1β, interleukin-1β; GOLM1, Golgi membrane protein 1; OPN, osteopontin; ABCG5, ATP-binding cassette subfamily G member; Chol, cholesterol; P, Phospholipid; BA, Bile Acid. Created in https://BioRender. com.
Abbreviations
ATP-binding cassette subfamily G members 5 and 8
cholesterol gallstone disease
fibroblast growth factor 21
metabolic dysfunction-associated steatohepatitis
metabolic dysfunction-associated steatotic liver disease
peroxisome proliferator-activated receptor gamma
REFERENCES
- 1. Lammert F, Gurusamy K, Ko CW, Miquel JF, Méndez-Sánchez N, Portincasa P, et al. Gallstones. Nat Rev Dis Primers 2016;2:16024.
- 2. Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 2005;7:132-140.
- 3. Su K, Sabeva NS, Liu J, Wang Y, Bhatnagar S, van der Westhuyzen DR, et al. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation. J Biol Chem 2012;287:28564-28575.
- 4. Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and non-alcoholic fatty liver disease: Multiple interactions. Int J Mol Sci 2017;18:1649.
- 5. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113-1124.
- 6. Bentanachs R, Miró L, Sánchez RM, Ramírez-Carrasco P, Amat C, Alegret M, et al. Pemafibrate abrogates SLD in a rat experimental dietary model, inducing a shift in fecal bile acids and microbiota composition. Biomed Pharmacother 2024;177:117067.
- 7. Wang Y, Xu H, Zhou X, Chen W, Zhou H. Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases. Med Rev (2021) 2024;4:262-283.
- 8. Zhang L, Shi Y, Liang B, Li X. An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD. Hepatol Commun 2024;8:e0434.
- 9. Greco S, Campigotto M, D’Amuri A, Fabbri N, Passaro A. Dyslipidemia, cholangitis and fatty liver disease: The close underexplored relationship: A narrative review. J Clin Med 2024;13:2714.
- 10. Shao WQ, Zhu WW, Luo MJ, Fan MH, Li Q, Wang SH, et al. Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma. Cell Rep 2022;39:110712.
- 11. Kasai K, Igarashi N, Tada Y, Kani K, Takano S, Yanagibashi T, et al. Impact of vancomycin treatment and gut microbiota on bile acid metabolism and the development of non-alcoholic steatohepatitis in mice. Int J Mol Sci 2023;24:4050.
- 12. Song Z, Wang Y, Lin P, Yang K, Jiang X, Dong J, et al. Identification of key modules and driving genes in nonalcoholic fatty liver disease by weighted gene co-expression network analysis. BMC Genomics 2023;24:414.
- 13. Li Y, Yang Y, Li Y, Zhang P, Ge G, Jin J, et al. Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis. J Int Med Res 2021;49:3000605211055378.
- 14. Wang F, Long Q, Gong Y, Hu L, Zhang H, Oettgen P, et al. Epithelium-Specific ETS (ESE)-1 upregulated GP73 expression in hepatocellular carcinoma cells. Cell Biosci 2014;4:76.
- 15. Li YT, Shao WQ, Chen ZM, Ma XC, Yi CH, Tao BR, et al. GOLM1 promotes cholesterol gallstone formation via ABCG5- mediated cholesterol efflux in metabolic dysfunction-associated steatohepatitis livers. Clin Mol Hepatol 2025;31:409-425.
- 16. Frans MT, Kuipers EM, Bianchi F, van den Bogaart G. Unveiling the impact of GOLM1/GP73 on cytokine production in cancer and infectious disease. Immunol Cell Biol 2023;101:727-734.
- 17. Pandak WM, Kakiyama G. The acidic pathway of bile acid synthesis: Not just an alternative pathway. Liver Res 2019;3:88-98.
- 18. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013;17:225-235.
- 19. Ciardullo S, Muraca E, Vergani M, Invernizzi P, Perseghin G. Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions. Gastroenterol Rep (Oxf) 2024;12:goae029.
Citations
Citations to this article as recorded by
- Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma
Shiji Fang, Liyun Zheng, Bin Lin, Jiale Chen, Dehai Hou, Yiming Ding, Mengzhu Han, Pan Qin, Mengyuan Wang, Xiaoju Guo, Yeyu Zhang, Gaofeng Shu, Fazong Wu, Jianfei Tu, Minjiang Chen, Zhongwei Zhao, Zhuang Liu, Jiansong Ji
Advanced Science.2026;[Epub] CrossRef - L. acidophilus prevents cholesterol gallstones in mice by regulating gut microbiota-mediated BAs metabolism and cholesterol homeostasis
Mengyan Du, Lvwang Ye, Cong Wang, Ting Jiang, Fang Liu
Journal of Functional Foods.2026; 139: 107194. CrossRef - GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
Clinical and Molecular Hepatology.2025; 31(2): e189. CrossRef - Reply to correspondence 2 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Nahee Hwang, Sungsoon Fang
Clinical and Molecular Hepatology.2025; 31(2): e228. CrossRef - Hyaluronic Acid Hydrogel Implants for Sustained Release of Oxaliplatin and Resiquimod to Prevent Hepatocellular Carcinoma Recurrence Post‐Radiofrequency Ablation
Yuezhan Shan, Hongyu Chu, Sheyu Ye, Guofeng Ji, Jiayi Zhao, Xinghui Si, Yumin Zhong, Youmao Tao, Jingwei Shi, Xuedong Fang
Advanced Science.2025;[Epub] CrossRef -
A demethylation chloroisosulochrin and a chromone metabolite from the endophytic fungus
Penicilium
sp.
Ke-Liang Chen, Xue Wang, Yang Liu, Yun-Bao Liu
Journal of Asian Natural Products Research.2025; : 1. CrossRef
